FDA
1 application listed (Prescription)Drugs@FDA lists 1 application naming this active ingredient: BLA022505. Marketing status as listed: Prescription. Checked 2026-10-05.
Drugs@FDA via openFDATesamorelin + Ipamorelin: blend, components and literature
A catalog item that supplies tesamorelin and ipamorelin together in one vial. The single compounds are listed separately.
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is Tesamorelin + Ipamorelin?
A catalog item that supplies tesamorelin and ipamorelin together in one vial. The single compounds are listed separately.
No formulation-level literature is listed. Each component's page lists its own studies. PubMed returns 6 records that mention every component in the title or abstract (checked 5 October 2026). This is a count of papers that name the components, not a count of studies of the combination.
Which compounds does Tesamorelin + Ipamorelin contain?
What is the regulatory status of each component?
Tesamorelin
EMA
Application withdrawnEMA medicines database (checked 5 October 2026): application withdrawn for EMEA/H/C/002427 on 2012-06-21. Centrally authorised procedures only.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "tesamorelin". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names tesamorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026Ipamorelin
FDA
No application listedNo application naming ipamorelin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDAEMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names ipamorelin as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "ipamorelin". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names ipamorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026The blend itself was not looked up as a product in the regulator databases; the component records above apply to the single compounds.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05; citations read from PubMed 2026-10-05.